|Bid||73.30 x 3100|
|Ask||73.75 x 1100|
|Day's Range||72.23 - 74.05|
|52 Week Range||56.26 - 83.85|
|Beta (3Y Monthly)||0.37|
|PE Ratio (TTM)||31.55|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.20 (2.65%)|
|1y Target Est||87.36|
Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.
Although sales of Clovis' (CLVS) Rubraca improved in the fourth quarter of 2018, the drug may face significant competition going forward. Clovis is also evaluating Rubrca for other cancer indications.
With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.
Share price of Novo Nordisk (NVO) has increased year to date on strong presence in the Diabetes Care market and a solid pipeline.
NOTE: On April 17, 2019, the press release was corrected as follows: In the third sentence, the description of the affirmed rating was changed to short term issuer rating. Revised release follows. Paris, April 16, 2019 -- Moody's Investors Service, ("Moody's") has today affirmed Merck KGaA's ('Merck') issuer rating, senior unsecured Medium Term Note and subordinated ratings at Baa1, (P)Baa1 and Baa3 respectively.
Moody's Investors Service ("Moody's") assigned an A2 rating to Bristol-Myers Squibb Company's ("Bristol") proposed new senior unsecured exchange note offering. The rating is under review for downgrade. There are no changes to Bristol's existing ratings including the A2 senior unsecured long-term rating or the Prime-1 short-term rating, and these ratings remain under review for downgrade.
Gilead (GILD) collaborates with data-driven company, Insitro, to harness the power of computers to discover and develop therapies for treating NASH (fatty liver).
Health care stocks have been in a strong uptrend, but closes below several key trendlines suggest that this could change.
J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...
Moody's Investors Service, ("Moody's") has today affirmed Merck KGaA's ('Merck') issuer rating, senior unsecured Medium Term Note and subordinated ratings at Baa1, (P)Baa1 and Baa3 respectively. Moody's has also affirmed the P-2 short term rating. The ratings affirmation follows Merck's announcement on 12 April, 2019 whereby it confirmed it had signed a definitive merger agreement to acquire Versum Materials ("Versum") for an enterprise value of E5.8 billion.
FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months
Merck (MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from ASPECT-NP, a randomized, double-blind, multi-center Phase 3 clinical trial evaluating the efficacy and safety of ZERBAXA® (ceftolozane and tazobactam) for the treatment of adult patients with ventilated nosocomial (hospital acquired) pneumonia. The results demonstrated non-inferiority of an investigational dose of ZERBAXA to meropenem, the active comparator, in the primary and key secondary endpoints.
The business combination received unanimous approval from the boards of the German pharmaceutical company and Versum, Merck said in a Friday press release. Versum is a supplier of process chemicals, gases and semiconductor manufacturing equipment.
Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Germany's Merck KGaA sealed a $6.5 billion (4.9 billion pounds) takeover deal with Versum Materials after overturning a deal it had agreed with rival bidder Entegris. A bet on a recovery in electronic materials markets for semiconductor makers, the transaction will boost the share of profit that diversified Merck derives from high-tech chemicals to 27 percent from 19 percent previously. Merck, also maker of pharmaceuticals and biotech production gear, this week won the backing of Versum's board for its $53-per-share offer, lifted from $48 previously, having been spurned for weeks.
Merck KGaA said Friday it has signed a definitive agreement to acquire Versum Materials Inc. in a deal with an enterprise value of 5.8 billion euros ($6.6 billion). Merck will pay $53 per Versum share in cash to create a top supplier of high-purity process chemicals, gases and equipment for semiconductor manufacturing, the company said in a statement. The deal is expected to immediately boost Merck's per-share earnings and to close in the second half. Versum's board has terminated its merger agreement with Entegris Inc. on the grounds that the Merck offer is superior. The deal will be financed with cash on hand and debt via a facilities agreement with Bank of America Merrill Lynch, BNP Paribas Fortis and Deutsche Bank AG. Merck is determined to maintain its strong investment grade rating, it said in a statement. Versum shares were slightly higher premarket, but have gained 38% in the past 12 months, while the S&P 500 has gained 8%.